News | May 19, 2014

Study Finds Gamma Knife Radiosurgery Alone Yields Equal Survival Outcomes for Patients With Two to 10 Tumors

Patients with five to 10 metastatic brain tumors who receive Gamma Knife radiosurgery live as long as those with two to four tumors post-therapy

May 19, 2014 — A Japanese multi-institutional study1 of 1,194 patients, has found that individuals with five to 10 tumors treated with Gamma Knife stereotactic radiosurgery alone (no whole brain radiation therapy) fared as well as a group with two to four tumors who received this radiosurgery-only treatment. The study on survivability after Gamma Knife radiosurgery was published online in The Lancet Oncology on March 10.

According to principle investigators Masaaki Yamamoto, M.D. and Toru Serizawa, M.D., these findings challenge the practice of inconsistent use of radiosurgery in patients with five or more brain metastases, for whom whole brain radiation therapy (WBRT) is often administered.  Neurocognitive deficits are a well-known side effect of WBRT.

"The study provides evidence in favor of offering Gamma Knife radiosurgery as the frontline treatment to patients with more than four brain mets," Yamamoto says. "It also provides a compelling reason to revise current guidelines for the management of these patients."

He adds that an ongoing prospective randomized study by The North American Gamma Knife Consortium could reinforce the implications of their study. The consortium is exploring neurocognitive outcomes in patients either treated with Gamma Knife alone or with whole brain radiation therapy for five or more brain mets (NCT01731704). The results are expected to further confirm the role of Gamma Knife radiosurgery without WBRT versus only WBRT for multiple brain mets.

Equal Overall Survival

The prospective observational study, completed by the Japanese Leksell Gamma Knife (JLGK) Society recruited 1,194 participants with one to as many as 10 brain mets from 23 hospitals in Japan. All patients were treated with single-session radiosurgery using Leksell Gamma Knife.

Median overall survival after Gamma Knife radiosurgery in all patients was 12 months. Median overall survival post-treatment was 13.9 months for patients with a single lesion. In both the 2-4 mets group and 5-10 mets group, median overall survival times were 10.8 months.

According to Yamamoto, "these results suggest that Gamma Knife radiosurgery without WBRT as the initial treatment for patients with five to 10 brain metastases is 'non-inferior' to stereotactic radiosurgery without WBRT in patients with two to four brain metastases — in terms of overall survival and most of the secondary endpoints.

"The essential criticism of employing Gamma Knife radiosurgery without WBRT for patients with several lesions is that microscopic tumors might go untreated, necessitating salvage stereotactic radiosurgery or an alternative therapy," he adds. "Thus, WBRT is widely advocated. However, a recent study showed that WBRT is only able to prevent the emergence of new tumors for no more than six months post-treatment. Many patients with brain mets can survive for more than a year, thereby outliving the effects of WBRT."

Penny K. Sneed, M.D., professor and vice chair, Department of Radiation Oncology, University of California, San Francisco, remarks that the multicenter research is an "important prospective study confirming what many Gamma Knife users have observed retrospectively for many years — that the number of brain metastases beyond a single lesion is not very important for survival time, local recurrence or toxicity, as long as the total tumor volume is limited."   


1. Yamamoto M, Serizawa T, Shuto T, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. The Lancet Oncol 2014:15:387-395

For more information:

Related Content

First FDA-Approved Study of Focused Ultrasound to Open Blood-Brain Barrier
News | Focused Ultrasound Therapy | August 21, 2018
In the first such clinical trial in the United States, physician-scientists with the University of Maryland School of...
Doctor-Patient Discussions Neglect Potential Harms of Lung Cancer Screening
News | Lung Cancer | August 15, 2018
August 15, 2018 — Although national guidelines advise doctors to discuss the benefits and harms of...
Videos | Radiation Therapy | August 13, 2018
ITN Editor Dave Fornell takes a tour of some of the innovative new technologies on the expo floor at the 2018 America
Videos | Radiation Therapy | August 13, 2018
A discussion with Mahadevappa Mahesh, MS, Ph.D., FAAPM, FACR, FACMP, FSCCT, professor of radiology and cardiology and
Videos | Proton Therapy | August 10, 2018
A discussion with Matthew Freeman, Ph.D., scientist at Los Alamos National Laboratory, New Mexico.
Videos | Radiomics | August 09, 2018
A discussion with Martin Vallieres, Ph.D., post-doctoral fellow at McGill University, Montreal, Canada.
Cardiac Imaging Reveals Roots of Preeclampsia Damage in Pregnant Women
News | Women's Health | August 07, 2018
Johns Hopkins researchers say a heart imaging study of scores of pregnant women with the most severe and dangerous form...
Cardiac Monitoring a Higher Priority for High-Risk Breast Cancer Patients
News | Cardio-oncology | August 07, 2018
August 7, 2018 — While heart failure is an uncommon complication of...
Videos | AAPM | August 03, 2018
Ehsan Samei, Ph.D., DABR, FAAPM, FSPIE, director of the Duke Un...
Videos | Radiation Therapy | August 01, 2018
This is an example of how Cherenkov radiation glow can be collected with image intensifier cameras during radiotherap
Overlay Init